Intra-arterial urokinase for acute ischemic stroke: factors associated with complications.
The authors abstracted the records of 43 patients treated with intra-arterial urokinase for acute ischemic stroke to identify predictors of serious complications. Sixteen (37%) had such a complication. Higher urokinase dose (>1.5 x 10(6) U), higher mean arterial blood pressure before treatment (>130 mm Hg), basilar occlusive strokes, and severe strokes were most predictive of these complications. Although urokinase is no longer manufactured, these findings identify patients at risk for complications from other intra-arterial thrombolytics.
Tirschwell
D L
DL
Department of Neurology, University of Washington, Seattle 98104-2499, USA. tirsch@u.washington.edu
Coplin
W M
WM
Becker
K J
KJ
Vogelzang
P
P
Eskridge
J
J
Haynor
D
D
Cohen
W
W
Newell
D
D
Winn
H R
HR
Longstreth
W T
WT
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002544:Cerebral Infarction / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D011785:Quality Assurance, Health Care; D012189:Retrospective Studies; D012307:Risk Factors; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects* / Q000627:therapeutic use
D014568:Urokinase-Type Plasminogen Activator